Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that v::ALK status confers therapeutic sensitivity to Brigatinib in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized brigatinib as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who were previously not treated with an ALK inhibitor.
This statement is based on a regulatory approval from the European Medicines Agency:
Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.